Ernesto Maddaloni, Anda M Naciu, Carmen Mignogna, Raffaele Galiero, Rocco Amendolara, Marta Fogolari, Chiara Satta, Chiara Serafini, Silvia Angeletti, Maria Gisella Cavallo, Efisio Cossu, Ferdinando Carlo Sasso, Raffaella Buzzetti, Paolo Pozzilli
AIM: To compare the efficacy and safety of saxagliptin/dapagliflozin and insulin glargine in people with latent autoimmune diabetes in adults (LADA). METHODS: In this phase 2b multicentre, open-label, comparator-controlled, parallel-group, non-inferiority study, we randomly assigned 33 people with LADA who had a fasting C-peptide concentration ≥0.2 nmol/L (0.6 ng/mL) to receive 1-year daily treatment with either the combination of saxagliptin (5 mg) plus dapagliflozin (10 mg) or insulin glargine (starting dose: 10 IU), both on top of metformin...
January 31, 2024: Diabetes, Obesity & Metabolism